Toshifumi Ohkusa Selected Research

Ulcerative Colitis

1/2021	Long-term outcomes of antibiotic combination therapy for ulcerative colitis.
1/2020	Efficacy and safety of short-term therapy with indigo naturalis for ulcerative colitis: An investigator-initiated multicenter double-blind clinical trial.
1/2014	Long-term alteration of intestinal microbiota in patients with ulcerative colitis by antibiotic combination therapy.
12/2013	Clinical significance of serum procalcitonin in patients with ulcerative colitis.
5/2013	The fatty acid profile of the erythrocyte membrane in initial-onset inflammatory bowel disease patients.
1/2011	Antibiotic combination therapy for steroid withdrawal in steroid-dependent ulcerative colitis.
10/2010	Peroxisome proliferator-activated receptor γ 2 mutation may cause a subset of ulcerative colitis.
8/2010	Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial.
5/2010	Efficacy of antibiotic combination therapy in patients with active ulcerative colitis, including refractory or steroid-dependent cases.
7/2009	Serial changes of cytokines in active ulcerative colitis: effects of antibiotic combination therapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Toshifumi Ohkusa Research Topics

Disease

27	Neoplasms (Cancer) 06/2017 - 03/2006
17	Ulcerative Colitis 01/2021 - 08/2002
10	Pancreatic Neoplasms (Pancreatic Cancer) 05/2016 - 06/2010
7	Wilms Tumor (Wilm's Tumor) 10/2020 - 08/2014
6	Infections 10/2013 - 02/2002
4	Adenocarcinoma 11/2021 - 10/2015
4	Crohn Disease (Crohn's Disease) 01/2018 - 08/2002
4	Hypersensitivity (Allergy) 10/2015 - 11/2006
4	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2015 - 03/2005
4	Colitis 11/2010 - 10/2002
3	Constipation 01/2019 - 12/2018
3	Inflammation (Inflammations) 01/2017 - 07/2004
3	Colorectal Neoplasms (Colorectal Cancer) 05/2016 - 05/2006
2	Diarrhea 01/2019 - 12/2018
2	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 01/2019 - 12/2018
2	Neoplasm Metastasis (Metastasis) 01/2015 - 12/2012
2	Gastritis 12/2014 - 12/2006
2	Hepatitis 02/2014 - 02/2010
2	Abscess 05/2009 - 04/2007
2	Dyspepsia (Indigestion) 12/2006 - 11/2005
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 01/2022
1	Fever (Fevers) 01/2021
1	Dysbiosis 01/2019
1	Glioma (Gliomas) 12/2016
1	Glioblastoma (Glioblastoma Multiforme) 12/2016
1	Varicose Veins (Varicose Vein) 05/2016
1	Hemorrhage 05/2016
1	Stomach Neoplasms (Stomach Cancer) 05/2016
1	Necrosis 01/2015
1	Peptic Ulcer (Peptic Ulcers) 12/2014
1	Breast Neoplasms (Breast Cancer) 09/2014
1	Leukemia 07/2014
1	Fibrosis (Cirrhosis) 02/2014

Drug/Important Bio-Agent (IBA)

15	AntigensIBA 05/2016 - 08/2002
12	Cancer VaccinesIBA 01/2019 - 01/2009
11	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 03/2005
8	Peptides (Polypeptides)IBA 10/2020 - 02/2014
8	VaccinesIBA 05/2016 - 01/2009
4	Metronidazole (Metric)FDA LinkGeneric 01/2021 - 11/2004
4	Amoxicillin (Wymox)FDA LinkGeneric 01/2021 - 11/2004
4	Gemcitabine FDA Link 12/2014 - 01/2011
3	Tetracycline (Achromycin)FDA LinkGeneric 01/2021 - 11/2005
3	HLA-DR Antigens (HLA-DR)IBA 01/2015 - 06/2010
3	CytokinesIBA 12/2013 - 05/2009
3	Transforming Growth Factors (Transforming Growth Factor)IBA 08/2013 - 01/2013
3	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 11/2010 - 02/2004
3	AcidsIBA 11/2006 - 08/2005
2	linaclotideIBA 01/2019 - 12/2018
2	16S Ribosomal RNAIBA 01/2019 - 01/2008
2	Pharmaceutical PreparationsIBA 01/2019 - 01/2007
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2018 - 05/2013
2	Chondroitin Sulfates (Chondroitin Sulfate)IBA 06/2017 - 01/2015
2	SulfotransferasesIBA 06/2017 - 01/2015
2	CarbohydratesIBA 06/2017 - 01/2015
2	Proteins (Proteins, Gene)FDA Link 01/2015 - 01/2013
2	Messenger RNA (mRNA)IBA 01/2015 - 10/2010
2	EpitopesIBA 11/2014 - 08/2014
2	Ethanol (Ethyl Alcohol)IBA 08/2013 - 01/2013
2	Interleukin-10 (Interleukin 10)IBA 01/2013 - 06/2010
2	Interleukin-2 (IL2)IBA 12/2012 - 05/2009
2	SteroidsIBA 01/2011 - 05/2010
2	adefovir dipivoxil (Hepsera)FDA Link 02/2010 - 01/2010
2	lipoarabinomannan (LAM)IBA 02/2010 - 01/2010
2	Lamivudine (Epivir)FDA Link 02/2010 - 01/2010
2	Bromodeoxyuridine (BrdU)IBA 08/2005 - 10/2002
2	Proton Pump InhibitorsIBA 11/2004 - 02/2002
2	Dextran SulfateIBA 01/2003 - 10/2002
1	Bacterial DNAIBA 01/2022
1	Immunologic Factors (Immunomodulators)IBA 11/2021
1	HLA Antigens (Human Leukocyte Antigens)IBA 10/2020
1	Indigo Carmine (Indigo Blue)IBA 01/2020
1	PrebioticsIBA 01/2019
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2018
1	Type V Secretion SystemsIBA 01/2017
1	Virulence Factors (Pathogenicity Factors)IBA 01/2017
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 12/2016
1	Temozolomide (Temodar)FDA LinkGeneric 12/2016
1	ParaffinIBA 12/2016
1	InterleukinsIBA 10/2015
1	Interleukin-6 (Interleukin 6)IBA 10/2015
1	2-mercaptopurineIBA 01/2015
1	EnzymesIBA 01/2015
1	Azathioprine (Imuran)FDA LinkGeneric 01/2015
1	Small Interfering RNA (siRNA)IBA 01/2015
1	A73025IBA 01/2015
1	Fluorouracil (Carac)FDA LinkGeneric 11/2014
1	LipopolysaccharidesIBA 07/2014
1	AntibodiesIBA 02/2014
1	WT1 ProteinsIBA 02/2014
1	Neurotrophin 3IBA 02/2014
1	lecithin-retinol acyltransferaseIBA 02/2014

Therapy/Procedure

19	Therapeutics 01/2021 - 02/2002
8	Immunotherapy 12/2016 - 01/2009
7	Drug Therapy (Chemotherapy) 01/2019 - 01/2011
1	Fecal Microbiota Transplantation 01/2019
1	Gastrectomy 05/2016
1	Sclerotherapy 05/2016
1	Immunomodulation 09/2014
1	Cryotherapy (Therapy, Cold) 09/2014
1	Aftercare (After-Treatment) 02/2014